HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	2/1/2005 4:42:36 AM
	of 1022

First MorphoSys-Generated Antibody Enters Clinical Trials in Partnered Program Tuesday February 1, 3:16 am ET MARTINSRIED and MUNICH, Germany, February 1 /PRNewswire-FirstCall/ -- MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX) announced today that GPC Biotech AG has commenced a Phase 1 clinical trial with a fully human cancer antibody generated using the MorphoSys' HuCAL(R) technology. The testing in human patients with the HuCAL(R)-generated antibody represents a significant milestone for MorphoSys, in that it is the first MorphoSys-generated antibody to be administered to humans. The commencement of clinical trials triggers a clinical milestone payment from GPC Biotech to MorphoSys. In December 2004, GPC Biotech received clearance from Swiss authorities to initiate human clinical testing with the HuCAL(R)-derived anticancer monoclonal antibody 1D09C3. In total, the clinical trials will involve three different sites in Europe and first commence at the Oncology Institute of Southern Switzerland (IOSI), a world-renowned oncology center that has been involved in numerous previous Phase 1 studies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next